Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 8, 2014, Pages 2304-2308

  Liu, Zeming ^a   Li, Xiaoyu ^a   Shi, Lan ^a   Maimaiti, Yusufu ^a   Chen, Tianwen ^a   Li, Zhi ^a   Wang, Shuntao ^a   Xiong, Yiquan ^a   Guo, Hui ^a   He, Wenshan ^a   Liu, Chunping ^a   Nie, Xiu ^a   Zeng, Wen ^a   Huang, Tao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Aggressive behavior; CK19; Galectin 3; HBME 1; Papillary thyroid carcinoma; TPO

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 19; GALECTIN 3; HECTOR BATTIFORA MESOTHELIAL EPITOPE 1; THYROID PEROXIDASE; UNCLASSIFIED DRUG;

ADULT; AGED; AGGRESSION; ARTICLE; CELL INVASION; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; THYROID CARCINOMA; TUMOR VOLUME;

EID: 84907212482     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Davies L and Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295: 2164-2167.
2. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K and Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005; 47: 391-401.
4. Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, Andre S, Gabius HJ and Laurent G. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 2008; 18: 705-712.
5. Cheng S, Serra S, Mercado M, Ezzat S and Asa SL. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res 2011; 17: 2385-2394.
6. Isic Dencic T, Cvejic D, Paunovic I, Tatic S, Havelka M and Savin S. Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior. Med Oncol 2013; 30: 362.
7. Li Z, Liu CP, Shi L and Huang T. [Operation for differentiated thyroid cancer: a experience of 546 cases]. Zhonghua Wai Ke Za Zhi 2008; 46: 375-377.
8. Udelsman R and Shaha AR. Is total thyroidectomy the best possible surgical management for well-differentiated thyroid cancer? Lancet Oncol 2005; 6: 529-531.
9. Zhao Q, Ming J, Liu C, Shi L, Xu X, Nie X and Huang T. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol 2013; 20: 746-752.
10. RA D. Pathology and genetics of tumours of endocrine organs. Lyon: World Health Organization; 2004.
11. Liu Z, Xun X, Wang Y, Mei L, He L, Zeng W, Wang CY and Tao H. MRI and ultrasonography detection of cervical lymph node metastases in differentiated thyroid carcinoma before reoperation. Am J Transl Res 2014; 6: 147-154.
12. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gomez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M and Schlumberger MJ. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13: 897-905.
13. Vini L and Harmer C. Management of thyroid cancer. Lancet Oncol 2002; 3: 407-414.
14. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K and Hirohashi K. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003; 94: 851-857.
15. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V and Roskams T. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49: 138-151.
16. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N and Trivedi TI. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 2001; 44: 523-533.
17. Jain R, Fischer S, Serra S and Chetty R. The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol 2010; 18: 9-15.
18. Gomez Saez JM. Diagnostic usefulness of tumor markers in the thyroid cytological samples extracted by fine-needle aspiration biopsy. Endocr Metab Immune Disord Drug Targets 2010; 10: 47-56.
19. Casey MB, Lohse CM and Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol 2003; 14: 55-60.
20. Wang N, Dong CR, Jiang R, Tang C, Yang L, Jiang QF, Chen GG and Liu ZM. Overexpression of HIF-1alpha, metallothionein and SLUG is associated with high TNM stage and lymph node metastasis in papillary thyroid carcinoma. Int J Clin Exp Pathol 2014; 7: 322-330.
21. Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S and Ozdamar SO. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol 2010; 21: 80-89.
22. Paunovic I, Isic T, Havelka M, Tatic S, Cvejic D and Savin S. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors. APMIS 2012; 120: 368-379.
23. Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X and Zhu X. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol 2010; 63: 786-789.
24. Wu G, Wang J, Zhou Z, Li T and Tang F. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity? J Int Med Res 2013; 41: 975-983.
25. Mataraci EA, Ozguven BY and Kabukcuoglu F. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions. Pol J Pathol 2012; 63: 58-64.